Latest News

(UroToday.com) In a session of the Best Kidney Cancer Poster Presentations at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, Dr. Truong presented an assessment of the prevalence of germline mutations in patients with kidney cancer. It has been accepted that approximately one-in-twenty (5%) of patients with renal cell carcinoma have a hereditary cause, […]

(UroToday.com) In a session of the Best Kidney Cancer Poster Presentations at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, Dr. Javier-Desloges sought to determine whether insurance expansions implemented through the Patient Protection and Affordable Care Act (ACA) were associated with changes in insurance coverage status, stage a diagnosis and overall survival in patients […]

(UroToday.com) At the Society of Urologic Oncology (SUO) Annual Meeting, Dr. James Wysock gave an update on the imaging for primary prostate cancer. Dr. Wysock briefly touched on imaging strategies in both the screening and diagnosis of localized prostate cancer.

(UroToday.com) The recent COVID-19 pandemic has emphasized the importance of remote interactions, as facilitated through telemedicine. However, there is a pre-existing need for remote care delivery. In a session of the Best Poster Presentations in Health Services and Other Research at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, Dr. Gadzinski pointed out that […]

(UroToday.com) At the Society of Urologic Oncology (SUO) Annual Virtual Meeting, Dr. Brian Shuch reviewed strategies for identifying renal masses as oncocytoma, a type of benign renal mass. Although not as common as renal cell carcinoma (RCC), oncocytomas are not uncommon and account for 3-5% of renal masses and approximately 25% of small renal masses.

(UroToday.com) To conclude the advances in prostate cancer session Drs. Matthew Cooperberg and Tanya Dorff debated whether prostate-specific membrane antigen (PSMA) imaging should be routinely used in the clinical management of prostate cancer.

Renal oncocytoma (RO) accounts for 5% of renal cancers and generally behaves as a benign tumor with favorable long-term prognosis. It is difficult to confidently distinguish between benign RO and other renal malignancies, particularly chromophobe renal cell carcinoma (chRCC).

(UroToday.com) As part of the panel discussion on biomarkers in testis cancer, Dr. Nabil Adra discussed the clinical application of these biomarkers. Dr. Adra notes that AFP, beta-HCG, and LDH are currently the only suitable biomarkers for testis cancer, which are elevated in ~60% of patients at primary diagnosis. However, conventional tumor markers lack specificity: AFP […]

(UroToday.com) Inguinal lymph node dissection is a core component in the management of penile squamous cell carcinoma with involvement, or a high risk of involvement, of the inguinal lymph nodes. The National Comprehensive Cancer Network (NCCN), guidelines recommend bilateral inguinal lymph node dissection for patients with clinically positive solitary non-bulky unilateral inguinal lymph nodes (cN1), and neoadjuvant chemotherapy […]

(UroToday.com) Dr. Peter Albers presented the first results of the PROBASE, Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBASE Trial, a randomized controlled trial of risk-adapted prostate cancer screening beginning in men at age 45 vs 50 years old.